Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience

TY - JOUR

T1 - Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience

AU - Striefler, Jana Käthe

AU - Brandes, Franziska

AU - Baur, Alexander

AU - Pfitzner, Berit Maria

AU - Kaul, David

AU - Rau, Daniel

AU - Dörr, Anne

AU - Schmiester, Maren

AU - Koulaxouzidis, Georgios

AU - Bullinger, Lars

AU - Märdian, Sven

AU - Flörcken, Anne

PY - 2020/1/29

Y1 - 2020/1/29

N2 - BACKGROUND: The antibody targeting platelet-derived growth factor receptor alpha (PDGFRA), olaratumab, was approved in 2016 for metastatic soft tissue sarcoma (STS) in combination with doxorubicin based on promising results of a phase Ib/II trial by the Food and Drug Administration (FDA). However, recently the phase III ANNOUNCE trial could not confirm the additional value of olaratumab in this context.METHODS: Here, in a retrospective analysis we share our single-centre experience with olaratumab/doxorubicin in STS by including n = 32 patients treated with olaratumab/doxorubicin between 2016 and 2019.RESULTS: Median progression-free survival (PFS) in the overall cohort was 3.1 months (range 0.6-16.2). A response [complete remission (CR), partial remission (PR) or stable disease (SD)] was seen in n = 11 (34%) cases, whereas n = 21 (66%) patients showed progressive disease (PD). In n = 9 patients surgery was performed subsequently in an individual therapeutic approach. Out of n = 5 patients receiving additional regional hyperthermia, n = 3 achieved PR or SD.CONCLUSIONS: This single-centre experience does also not support the promising phase Ib/II results for olaratumab/doxorubicin in STS. However, our findings do not preclude that olaratumab combination therapy could be valuable in a neoadjuvant setting. This warrants further exploration also taking into account the heterogeneous nature of STS.

AB - BACKGROUND: The antibody targeting platelet-derived growth factor receptor alpha (PDGFRA), olaratumab, was approved in 2016 for metastatic soft tissue sarcoma (STS) in combination with doxorubicin based on promising results of a phase Ib/II trial by the Food and Drug Administration (FDA). However, recently the phase III ANNOUNCE trial could not confirm the additional value of olaratumab in this context.METHODS: Here, in a retrospective analysis we share our single-centre experience with olaratumab/doxorubicin in STS by including n = 32 patients treated with olaratumab/doxorubicin between 2016 and 2019.RESULTS: Median progression-free survival (PFS) in the overall cohort was 3.1 months (range 0.6-16.2). A response [complete remission (CR), partial remission (PR) or stable disease (SD)] was seen in n = 11 (34%) cases, whereas n = 21 (66%) patients showed progressive disease (PD). In n = 9 patients surgery was performed subsequently in an individual therapeutic approach. Out of n = 5 patients receiving additional regional hyperthermia, n = 3 achieved PR or SD.CONCLUSIONS: This single-centre experience does also not support the promising phase Ib/II results for olaratumab/doxorubicin in STS. However, our findings do not preclude that olaratumab combination therapy could be valuable in a neoadjuvant setting. This warrants further exploration also taking into account the heterogeneous nature of STS.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Antibodies, Monoclonal/administration & dosage

KW - Antineoplastic Combined Chemotherapy Protocols/adverse effects

KW - Combined Modality Therapy

KW - Doxorubicin/administration & dosage

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Neoplasm Grading

KW - Neoplasm Metastasis

KW - Neoplasm Staging

KW - Retrospective Studies

KW - Soft Tissue Neoplasms/drug therapy

KW - Treatment Outcome

U2 - 10.1186/s12885-020-6551-y

DO - 10.1186/s12885-020-6551-y

M3 - SCORING: Journal article

C2 - 31996176

VL - 20

JO - BMC CANCER

JF - BMC CANCER

SN - 1471-2407

IS - 1

M1 - 68

ER -